Purpose: Eravacycline is a broad-spectrum, intravenous fluorocycline antibiotic approved for the treatment of complicated intra-abdominal infections in adults. A 60-minute infusion is recommended for each infused dose. Compatibility data that may allow convenient Y-site administration of eravacycline with other parenteral medications are unavailable. We aimed to determine the physical compatibility of eravacycline with other intravenous medications by simulated Y-site administration.
Methods: Eravacycline was reconstituted according to published prescribing information and diluted with 0.9% sodium chloride to a concentration of 0.6 mg/mL. Simulated Y-site administration was performed by mixing 5 mL of eravacycline with an equal volume of 51 other intravenous medications, including crystalloid and carbohydrate hydration fluids and 20 antimicrobials. Secondary medications were assessed at the upper range of concentrations considered standard for intravenous infusion. Mixtures underwent visual inspection and turbidity measurement immediately on mixture and at 3 subsequent time points (30, 60, and 120 minutes after admixture), and pH was measured at 60 minutes for comparison with the baseline value of the secondary medication.
Findings: Eravacycline was physically compatible with 41 parenteral drugs (80%) by simulated Y-site administration. Incompatibility was observed with albumin, amiodarone hydrochloride, ceftaroline fosamil, colistimethate sodium, furosemide, meropenem, meropenem/vaborbactam, micafungin sodium, propofol, and sodium bicarbonate.
Implications: Eravacycline for injection was physically compatible with most parenteral medications assessed. Pharmacists and nurses should be knowledgeable of the observed incompatibilities with eravacycline to prevent the unintentional mixing of incompatible intravenous medications.
Keywords: eravacycline; incompatible; intravenous administration; medication safety profile; multidrug resistance.
Copyright © 2019 Elsevier Inc. All rights reserved.
Physical Compatibility of Meropenem and Vaborbactam With Select Intravenous Drugs During Simulated Y-site Administration.Clin Ther. 2018 Feb;40(2):261-269. doi: 10.1016/j.clinthera.2017.12.007. Epub 2017 Dec 28. Clin Ther. 2018. PMID: 29290374
Physical compatibility of isavuconazonium sulfate with select i.v. drugs during simulated Y-site administration.Am J Health Syst Pharm. 2017 Jan 1;74(1):e55-e63. doi: 10.2146/ajhp150733. Epub 2016 Dec 22. Am J Health Syst Pharm. 2017. PMID: 28007722
Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration.Am J Health Syst Pharm. 2011 Dec 1;68(23):2265-70. doi: 10.2146/ajhp100663. Am J Health Syst Pharm. 2011. PMID: 22095816
Eravacycline: A Review in Complicated Intra-Abdominal Infections.Drugs. 2019 Feb;79(3):315-324. doi: 10.1007/s40265-019-01067-3. Drugs. 2019. PMID: 30783960 Free PMC article. Review.
Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent.Drugs. 2016 Apr;76(5):567-88. doi: 10.1007/s40265-016-0545-8. Drugs. 2016. PMID: 26863149 Review.